The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Subscribe To Our Newsletter & Stay Updated
